Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy involves the intratendinous injection of autologous adipose tissue-derived mesenchymal stem cells (AD MSCs) for the treatment of rotator cuff disease, specifically partial-thickness rotator cuff tears. Developed by researchers at Seoul National University Hospital and SMG-SNU Boramae Medical Center, the treatment utilizes the patient's own mesenchymal stem cells harvested from fat tissue. The therapy aims to improve shoulder function and relieve pain by promoting the regeneration of the rotator cuff tendon. Clinical evaluation has included a Phase 1 dose-escalation study assessing safety and efficacy across low, mid, and high-dose cohorts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous adipose tissue-derived mesenchymal stem cells (Seoul National University Hospital).